B-cell receptor specific for Human Papillomavirus type 18 L1 conformational epitopes

B-cell receptors (BCRs) specific for Human Papillomavirus type 18 (HPV18) L1 conformational epitopes are the primary immunological targets for prophylactic HPV vaccines (Source: PubMed, PMID: 25443825). These receptors are membrane-bound immunoglobulins expressed on the surface of B lymphocytes that possess high affinity for the structural motifs of the HPV18 major capsid protein, L1, when assembled into virus-like particles (VLPs) (Source: UniProt, P06794). Upon binding to these conformational epitopes, the BCR undergoes cross-linking, which triggers intracellular signaling pathways leading to B-cell activation, clonal expansion, and the eventual secretion of high-titer neutralizing antibodies (Source: NIH, StatPearls). These antibodies are essential for preventing HPV18 infection, which is a major causative agent of cervical, anogenital, and oropharyngeal cancers (Source: WHO). Therapeutic intervention via vaccination with products like Gardasil or Cervarix aims to stimulate these specific BCRs to establish long-term humoral immunity and immunological memory against the virus (Source: FDA, Package Inserts).

Other names

HPV18 L1-specific B-cell receptorAnti-HPV18 L1 BCRHuman Papillomavirus 18 L1-specific BCRBCR specific for HPV18 L1 VLPs

The mechanism of action involves the binding of vaccine-delivered HPV18 L1 virus-like particles (VLPs) to specific B-cell receptors (BCRs) on naive B cells. This binding event, which requires the preservation of conformational epitopes on the L1 protein, induces BCR clustering and signaling, leading to B-cell activation, antigen internalization, and subsequent differentiation into plasma cells that produce neutralizing antibodies and long-lived memory B cells (Source: PubMed, PMID: 16126462).